Transave

About:

Transave is a biotechnology company developing inhaled pharmaceuticals for the treatment of lung diseases.

Top Investors: Bessemer Venture Partners, F-Prime Capital, Eight Roads Ventures, Forbion Capital Partners, TVM Capital

Description:

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

Total Funding Amount:

$58.5M

Headquarters Location:

Monmouth Junction, New Jersey, United States

Founded Date:

1997-01-01

Founders:

Patrick McBrayer

Number of Employees:

11-50

Last Funding Date:

2010-06-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai